ENVB
Income statement / Annual
Last year (2024), Enveric Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Enveric Biosciences, Inc.'s net income was -$9.57 M.
See Enveric Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$39.91 M |
$43.00 M |
$48.59 M |
$36.15 M |
$15.98 M |
| Cost of Revenue |
$0.00
|
$408,030.00
|
$435,201.00
|
$681,612.00
|
$120,872.00
|
$31.76 M
|
$34.01 M
|
$38.36 M
|
$29.61 M
|
$10.23 M
|
| Gross Profit |
$0.00
|
-$408,030.00
|
-$435,201.00
|
-$681,612.00
|
-$120,872.00
|
$8.15 M
|
$8.98 M
|
$10.24 M
|
$6.54 M
|
$5.75 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0.2
|
0.21
|
0.21
|
0.18
|
0.36
|
| Research and Development Expenses |
$2.84 M
|
$7.25 M
|
$8.03 M
|
$4.79 M
|
$174,083.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$6.45 M
|
$8.85 M
|
$11.61 M
|
$20.50 M
|
$5.44 M
|
$2,296.53
|
$0.00
|
$0.00
|
$8.55 M
|
$5.69 M
|
| Selling & Marketing Expenses |
$0.00
|
-$64,048.00
|
$0.00
|
$0.00
|
$0.00
|
$12.21 M
|
$0.00
|
$0.00
|
$417,249.00
|
$119,847.00
|
| Selling, General & Administrative Expenses |
$6.45 M
|
$8.79 M
|
$11.61 M
|
$20.50 M
|
$5.44 M
|
$12.21 M
|
$10.79 M
|
$18.51 M
|
$8.97 M
|
$5.81 M
|
| Other Expenses |
$337,489.00
|
$0.00
|
$327,910.00
|
$656,643.00
|
-$802,109.00
|
$2.27 M
|
$88,161.00
|
$1.08 M
|
-$394,213.00
|
$157,941.00
|
| Operating Expenses |
$9.63 M
|
$16.04 M
|
$19.96 M
|
$25.94 M
|
$5.62 M
|
$14.48 M
|
$13.70 M
|
$21.73 M
|
$10.33 M
|
$5.97 M
|
| Cost And Expenses |
$0.00
|
$16.45 M
|
$19.96 M
|
$25.94 M
|
$5.62 M
|
$46.24 M
|
$47.71 M
|
$60.08 M
|
$39.94 M
|
$16.19 M
|
| Interest Income |
$0.00
|
$0.00
|
$5.25
|
$10.32
|
$445.25
|
$81.82
|
$0.00
|
$0.00
|
$0.00
|
$89,918.00
|
| Interest Expense |
$0.00
|
$3,708.00
|
$5,249.00
|
$10,316.00
|
$445,250.00
|
$691,138.00
|
$729,896.00
|
$575,039.00
|
$751,074.00
|
$238,471.00
|
| Depreciation & Amortization |
$337,489.00
|
$408,030.00
|
$435,201.00
|
$681,612.00
|
$120,872.00
|
$2.27 M
|
$2.90 M
|
$3.22 M
|
$1.36 M
|
$157,941.00
|
| EBITDA |
-$9.25 M |
-$16.85 M |
-$19.63 M |
-$63.97 M |
-$6.30 M |
-$2.33 M |
-$6.92 M |
-$7.67 M |
-$4.41 M |
-$537,780.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-0.1
|
-0.04
|
-0.15
|
-0.08
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-0.16
|
-0.17
|
-0.25
|
-0.15
|
-0.12
|
| Total Other Income/Expenses Net |
$66,209.00
|
-$814,379.00
|
$7.46 M
|
$8.19 M
|
-$1.25 M
|
-$2.41 M
|
-$10.55 M
|
-$11.47 M
|
-$2.73 M
|
-$1.23 M
|
| Income Before Tax |
-$9.57 M
|
-$17.26 M
|
-$19.96 M
|
-$56.43 M
|
-$6.86 M
|
-$5.22 M
|
-$10.55 M
|
-$11.47 M
|
-$6.53 M
|
-$2.02 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-0.13
|
-0.25
|
-0.24
|
-0.18
|
-0.13
|
| Income Tax Expense |
-$8,930.00
|
$28,913.00
|
-$1.49 M
|
-$7.45 M
|
-$477,731.00
|
$388,657.00
|
$6.35 M
|
-$2.39 M
|
-$3.75 M
|
-$128,460.00
|
| Net Income |
-$9.57 M
|
-$17,291.73
|
-$18.47 M
|
-$48.98 M
|
-$6.39 M
|
-$5.60 M
|
-$16.90 M
|
-$9.07 M
|
-$2.78 M
|
-$1.89 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-0.14
|
-0.39
|
-0.19
|
-0.08
|
-0.12
|
| EPS |
-19.04 |
-8.09 |
-12.77 |
-103.69 |
-55.5 |
-211.99 |
-3551.39 |
-3028.98 |
-1064.17 |
-856.06 |
| EPS Diluted |
-19.04 |
-8.09 |
-12.77 |
-103.69 |
-55.5 |
-211.99 |
-3551.39 |
-3028.98 |
-1064.17 |
-851.69 |
| Weighted Average Shares Out |
$502,900.00
|
$2.16 M
|
$1.45 M
|
$472,342.00
|
$115,071.00
|
$26,435.00
|
$4,758.00
|
$2,996.00
|
$2,613.00
|
$2,374.00
|
| Weighted Average Shares Out Diluted |
$502,900.00
|
$2.16 M
|
$1.45 M
|
$472,342.00
|
$115,071.00
|
$26,435.00
|
$4,758.00
|
$2,996.00
|
$2,613.00
|
$2,220.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
